MarketCapExport financials
ClearPoint Neuro (CLPT)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
ClearPoint Neuro Balance Sheet 2025-2009 | CLPT
Brief overview of ClearPoint Neuro's financial position
This overview follows the five latest available annual observations between 2021 and 2025.
Assets reached $97.7 million, compared with $65.6 million at the beginning. Growth of +49% and CAGR near 10.5% show active expansion.
Asset growth of +49% came with a +315.2% rise in liabilities. Financial leverage became more prominent.
The share of internal funding stands at 28.7% versus 74.4% initially, providing a reasonable foundation.
Net debt is $3.8 million, or 0.14x of equity. This is a conservative debt position.
Cash accounts for 47% of assets versus 82.5% initially. The change indicates the degree of financial flexibility.
The accumulated result is -$216.9 million and remains below zero. The number alone does not explain whether losses, dividends or repurchases were the main cause.
Overall assessment
ClearPoint Neuro has a workable but not unconditionally strong balance sheet. Resilience depends on sustained earnings and liability control.
Annual Balance Sheet ClearPoint Neuro
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
3.85 M | -16.5 M | -12.8 M | -17.2 M | -43.8 M | 3.18 M | -3.23 M | 380 K | -4.37 M | 1.18 M | 2.7 M | -1.55 M | 4.91 M | 576 K | 7.31 M | - | - |
Long Term Debt |
49.1 M | 3.01 M | 9.95 M | 9.89 M | 9.84 M | 21.3 M | 2.07 M | 3.48 M | 2.92 M | 4.49 M | 3.89 M | 7.69 M | 4.08 M | 2.2 M | 3.5 M | - | - |
Long Term Debt Current |
694 K | 557 K | 424 K | 561 K | 507 K | 394 K | 114 K | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
59 M | 3.45 M | 14.1 M | 11.8 M | 12 M | 23.9 M | 3.51 M | 4.34 M | 3.67 M | 5.14 M | 4.43 M | 8.57 M | 4.62 M | 7.11 M | 10.3 M | - | - |
Total Current Liabilities |
10.8 M | 10.4 M | 7.43 M | 6.79 M | 4.75 M | 3.2 M | 3.83 M | 2.01 M | 4.4 M | 3.02 M | 7.65 M | - | 10.1 M | 6.31 M | 14.6 M | - | - |
Total Liabilities |
69.7 M | 13.8 M | 21.5 M | 18.6 M | 16.8 M | 27.1 M | 7.34 M | 6.35 M | 8.07 M | 8.16 M | 12.1 M | 13.5 M | 14.7 M | 11.3 M | 24.9 M | - | - |
Deferred Revenue |
1.67 M | 2.12 M | 2.61 M | 1.07 M | 678 K | 562 K | 1.02 M | 351 K | 256 K | 223 K | 116 K | 103 K | 107 K | 763 K | 2.6 M | - | - |
Retained Earnings |
-217 M | -191 M | -172 M | -150 M | -134 M | -120 M | -113 M | -107 M | -101 M | -93.9 M | -85.7 M | -77.3 M | - | - | - | - | - |
Total Assets |
97.7 M | 39.2 M | 42.7 M | 55.5 M | 65.6 M | 29.5 M | 11.9 M | 7.86 M | 13.9 M | 7.4 M | 10.1 M | 13.4 M | 7.87 M | 5.55 M | 3.03 M | - | - |
Cash and Cash Equivalents |
45.9 M | 20.1 M | 23.1 M | 27.6 M | 54.1 M | 20.1 M | 5.7 M | 3.1 M | 9.29 M | 3.32 M | 5.41 M | 9.24 M | 3.52 M | 1.62 M | 145 K | 1.58 M | 2.57 M |
Book Value |
28 M | 25.4 M | 21.2 M | 36.9 M | 48.8 M | 2.38 M | 4.59 M | 1.51 M | 5.83 M | -756 K | -1.98 M | -100 K | -6.83 M | -5.74 M | -21.8 M | - | - |
Total Shareholders Equity |
28 M | 25.4 M | 21.2 M | 36.9 M | 48.8 M | 2.38 M | 4.59 M | 1.51 M | 5.83 M | -756 K | -1.98 M | -100 K | -6.83 M | -7.87 M | -21.8 M | -15.3 M | -9.89 M |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Balance Sheet ClearPoint Neuro
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
22.7 M | 13.5 M | 13.7 M | 8.46 M | 6.2 M | 6.28 M | 2.86 M | 3.01 M | 3.16 M | 3.3 M | 3.44 M | 3.57 M | 3.7 M | 3.86 M | 1.39 M | 1.53 M | 1.54 M | 1.67 M | 1.81 M | 1.94 M | 2.07 M | 2.2 M | 2.33 M | 2.45 M | 205 K | 228 K | 255 K | 277 K | 300 K | 332 K | 367 K | 3.48 M | - | 3.33 M | 5.05 M | 4.92 M | 4.79 M | 4.69 M | 4.59 M | 4.49 M | 4.39 M | 6.05 M | 8.25 M | 8.11 M | 8 M | 7.89 M | 11 M | 11 M | - | - | - | - | - | - | - | - | - | - | 193 K | 194 K | - | - | - |
Total Non Current Liabilities |
75.6 M | 65.7 M | 65.1 M | 59 M | 36.4 M | 35.7 M | 3.22 M | 3.45 M | 3.64 M | 3.75 M | 3.9 M | 14.1 M | 14.2 M | 14 M | 11.6 M | 11.8 M | 11.8 M | 11.9 M | 12.1 M | 12 M | 20 M | 20 M | 27.2 M | 23.9 M | 18 M | 17.9 M | 17.2 M | 3.51 M | 3.1 M | 3.11 M | 4.91 M | 4.48 M | 4.17 M | 2.08 M | 1.95 M | 3.67 M | 5.53 M | 5.39 M | 5.17 M | 5.14 M | 5.05 M | 6.77 M | 8.68 M | 4.26 M | 4.35 M | 4.26 M | 8.75 M | 8.57 M | 8.4 M | 8.23 M | 8.07 M | 4.62 M | 8.82 M | 8.69 M | 8.57 M | 7.11 M | 7.03 M | 6.95 M | 7.09 M | - | - | - | - |
Total Liabilities |
85.5 M | 76 M | 74.6 M | 69.7 M | 44.5 M | 43.1 M | 10.1 M | 13.8 M | 11.2 M | 20.4 M | 19.1 M | 21.5 M | 19.7 M | 20.2 M | 17.7 M | 18.6 M | 17.9 M | 17.4 M | 16 M | 16.8 M | 24.6 M | 24.4 M | 30.3 M | 27.1 M | 21.7 M | 21.7 M | 20.8 M | 7.34 M | 7.38 M | 6.36 M | 7.18 M | 6.35 M | 6.19 M | 8.03 M | 7.6 M | 8.07 M | 8.18 M | 8.32 M | 8.4 M | 8.16 M | 8.44 M | 10.4 M | 11.9 M | 11.9 M | 12.1 M | 13.7 M | 14.4 M | 13.5 M | 14.4 M | 13 M | 13.2 M | 14.7 M | 15.1 M | 13.8 M | 14.9 M | 13.4 M | 16.9 M | 13.4 M | 16.8 M | 24.9 M | 24.9 M | 24.9 M | 24.9 M |
Deferred Revenue |
1.55 M | 1.84 M | 1.81 M | 1.67 M | 1.72 M | 1.38 M | 1.62 M | 2.12 M | 1.25 M | 1.08 M | 1.23 M | 2.61 M | 1.18 M | 724 K | 1.28 M | 1.07 M | 735 K | 675 K | 541 K | 678 K | 440 K | 368 K | 501 K | 562 K | 768 K | 620 K | 858 K | 1.02 M | 1.1 M | 740 K | 679 K | 211 K | 421 K | 215 K | 217 K | 256 K | 282 K | 426 K | 263 K | 223 K | 222 K | 223 K | 152 K | 116 K | 166 K | 73.2 K | 97.8 K | 103 K | 94.1 K | 34 K | 125 K | 107 K | 110 K | 75.8 K | 107 K | 113 K | 113 K | 113 K | 113 K | - | - | - | - |
Retained Earnings |
-245 M | -238 M | -226 M | -217 M | -209 M | -203 M | -197 M | -191 M | -186 M | -181 M | -177 M | -172 M | -168 M | -163 M | -156 M | -150 M | -146 M | -142 M | -138 M | -134 M | -130 M | -126 M | -122 M | -120 M | -118 M | -116 M | -115 M | -113 M | -111 M | -110 M | -108 M | -107 M | -106 M | -105 M | -103 M | -101 M | -99 M | -97.5 M | -95.5 M | -93.9 M | -92.2 M | -89.6 M | -87.8 M | -85.7 M | -84.5 M | -84.3 M | -81.2 M | -77.3 M | -75.4 M | -71.7 M | -70.1 M | -72.8 M | -71 M | -67.8 M | -66.5 M | -65.7 M | -66.6 M | -65.7 M | -63.3 M | -59.8 M | -59.8 M | -59.8 M | -59.8 M |
Total Assets |
113 M | 86.7 M | 93.4 M | 97.7 M | 60.4 M | 62.9 M | 30.1 M | 39.2 M | 40.2 M | 52.6 M | 53.6 M | 42.7 M | 43.8 M | 47.6 M | 50.2 M | 55.5 M | 57.7 M | 60.2 M | 61.8 M | 65.6 M | 68.7 M | 72.3 M | 74.3 M | 29.5 M | 21.8 M | 23 M | 23.6 M | 11.9 M | 13.4 M | 13.3 M | 7.63 M | 7.86 M | 8.68 M | 11.6 M | 12.3 M | 13.9 M | 15.5 M | 16.9 M | 6.19 M | 7.4 M | 9.01 M | 6.44 M | 8.29 M | 9.94 M | 6.27 M | 7.86 M | 10.7 M | 13.4 M | 6.5 M | 8.48 M | 10 M | 7.87 M | 9.52 M | 11 M | 13 M | 5.55 M | 7.49 M | 5.55 M | 4.07 M | 3.03 M | 3.03 M | 3.03 M | 3.03 M |
Cash and Cash Equivalents |
47.1 M | 30.3 M | 36.5 M | 47 M | 38.4 M | 41.7 M | 12.4 M | 20.1 M | 21.6 M | 32.8 M | 35.4 M | 23.1 M | 24.3 M | 26.5 M | 21.8 M | 27.6 M | 18.7 M | 23.5 M | 49.7 M | 54.1 M | 57.7 M | 61.5 M | 64.9 M | 20.1 M | 14.7 M | 16 M | 17 M | 5.7 M | 6.24 M | 7.46 M | 2.49 M | 3.1 M | 3.71 M | 6.7 M | 7.51 M | 9.29 M | 11 M | 1.97 M | 1.97 M | 3.32 M | 4.43 M | 2.02 M | 3.58 M | 5.41 M | 1.85 M | 3.52 M | 6.44 M | 9.24 M | 1.89 M | 4.08 M | 5.8 M | 3.52 M | 5.03 M | 6.98 M | 9.2 M | 1.62 M | 3.79 M | 1.62 M | 1.68 M | 145 K | 145 K | 145 K | 145 K |
Book Value |
27.3 M | 10.8 M | 18.8 M | 28 M | 15.9 M | 19.7 M | 20 M | 25.4 M | 29 M | 32.1 M | 34.6 M | 21.2 M | 24.1 M | 27.4 M | 32.6 M | 36.9 M | 39.9 M | 42.8 M | 45.7 M | 48.8 M | 44.1 M | 48 M | 44 M | 2.38 M | 149 K | 1.34 M | 2.76 M | 4.59 M | 6.01 M | 6.91 M | 443 K | 1.51 M | 2.49 M | 3.56 M | 4.75 M | 5.83 M | 7.28 M | 8.53 M | -2.2 M | -756 K | 575 K | -3.96 M | -3.61 M | -1.98 M | -5.82 M | -5.88 M | -3.63 M | -100 K | -7.93 M | -4.51 M | -3.14 M | -6.83 M | -5.61 M | -2.82 M | -1.87 M | -7.87 M | -9.42 M | -7.87 M | -12.7 M | -21.8 M | -21.8 M | -21.8 M | -21.8 M |
Total Shareholders Equity |
27.3 M | 10.8 M | 18.8 M | 28 M | 15.9 M | 19.7 M | 20 M | 25.4 M | 29 M | 32.1 M | 34.6 M | 21.2 M | 24.1 M | 27.4 M | 32.6 M | 36.9 M | 39.9 M | 42.8 M | 45.7 M | 48.8 M | 44.1 M | 48 M | 44 M | 2.38 M | 149 K | 1.34 M | 2.76 M | 4.59 M | 6.01 M | 6.91 M | 443 K | 1.51 M | 2.49 M | 3.56 M | 4.75 M | 5.83 M | 7.28 M | 8.53 M | -2.2 M | -756 K | 575 K | -3.96 M | -3.61 M | -1.98 M | -5.82 M | -5.88 M | -3.63 M | -100 K | -7.93 M | -4.51 M | -3.14 M | -6.83 M | -5.61 M | -2.82 M | -1.87 M | -7.87 M | -9.42 M | -7.87 M | -12.7 M | -21.8 M | -21.8 M | -21.8 M | -21.8 M |
Quarterly performance
Select metrics to display
All numbers in USD currency
Balance Sheet is a fundamental financial report of ClearPoint Neuro, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
Balance sheet of other industry stocks – Medical devices
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Avinger
AVGR
|
- | -20.74 % | $ 369 K |  USA |
 |
Medtronic PLC
MDT
|
$ 101.83 | -2.9 % | $ 131 B | USA |
 |
ThermoGenesis Holdings
THMO
|
- | -25.84 % | $ 171 K | USA |
 |
MiMedx Group
MDXG
|
$ 3.31 | 0.91 % | $ 489 M | USA |
 |
Talis Biomedical Corporation
TLIS
|
- | 3.55 % | $ 7.96 M | USA |
 |
Cognyte Software Ltd.
CGNT
|
$ 8.1 | 0.06 % | $ 591 M |  Israel |
 |
Myomo
MYO
|
$ 1.21 | 1.68 % | $ 50.6 M | USA |
 |
CONMED Corporation
CNMD
|
$ 51.44 | -2.42 % | $ 1.6 B | USA |
 |
Nano-X Imaging Ltd.
NNOX
|
$ 0.24 | -3.95 % | $ 15.5 M | Israel |
 |
Penumbra
PEN
|
$ 319.32 | -0.59 % | $ 12.4 B | USA |
 |
Viveve Medical
VIVE
|
- | -15.35 % | $ 1.71 M | USA |
 |
Insulet Corporation
PODD
|
$ 146.61 | -6.09 % | $ 10.3 B | USA |
 |
Smith & Nephew plc
SNN
|
$ 31.16 | -2.72 % | $ 27 B |  Britain |
 |
Stryker Corporation
SYK
|
$ 325.34 | -2.9 % | $ 124 B | USA |
 |
Tactile Systems Technology
TCMD
|
$ 26.03 | -0.83 % | $ 595 M | USA |
 |
TELA Bio
TELA
|
$ 0.82 | 5.24 % | $ 38.5 M | USA |
 |
TransMedics Group
TMDX
|
$ 87.58 | 26.96 % | $ 2.98 B | USA |
 |
SmileDirectClub
SDC
|
- | -53.45 % | $ 9.71 M | USA |
 |
Tandem Diabetes Care
TNDM
|
$ 16.63 | -7.59 % | $ 1.13 B | USA |
 |
Acutus Medical
AFIB
|
- | -26.83 % | $ 2.62 M | USA |
 |
BIOLASE
BIOL
|
- | -13.19 % | $ 166 K | USA |
 |
Viemed Healthcare
VMD
|
$ 9.14 | 1.39 % | $ 356 M | USA |
 |
SeaSpine Holdings Corporation
SPNE
|
- | 0.28 % | $ 270 M | USA |
 |
Varex Imaging Corporation
VREX
|
$ 18.45 | 0.03 % | $ 764 M | USA |
 |
Vivos Therapeutics
VVOS
|
$ 0.09 | -8.67 % | $ 925 K | USA |
 |
Apollo Endosurgery
APEN
|
- | - | $ 475 M | USA |
 |
Beyond Air
XAIR
|
$ 2.15 | -1.38 % | $ 17.8 B | USA |
 |
NuVasive
NUVA
|
- | - | $ 2.07 B | USA |
 |
Xtant Medical Holdings
XTNT
|
$ 0.28 | -5.0 % | $ 39.1 M | USA |
 |
Zimmer Biomet Holdings
ZBH
|
$ 105.43 | -1.42 % | $ 20.9 B | USA |
 |
Conformis
CFMS
|
- | - | $ 16.4 M | USA |
 |
ViewRay
VRAY
|
- | 1.54 % | $ 468 M | USA |
 |
Medigus Ltd.
MDGS
|
- | 10.28 % | $ 55.5 M | Israel |
 |
Cutera
CUTR
|
- | -10.19 % | $ 1.99 M | USA |
 |
Neovasc
NVCN
|
- | - | $ 111 M |  Canada |
 |
Vapotherm
VAPO
|
- | 6.72 % | $ 34 M | USA |
 |
Nevro Corp.
NVRO
|
- | - | $ 217 M | USA |
 |
Venus Concept
VERO
|
- | - | $ 726 K | USA |
 |
Eargo
EAR
|
- | - | $ 10.2 M | USA |
 |
Sientra
SIEN
|
- | -16.59 % | $ 10.3 M | USA |
 |
Silk Road Medical, Inc
SILK
|
- | - | $ 1.07 B | USA |
 |
Surgalign Holdings
SRGA
|
- | -32.98 % | $ 1.68 M | USA |
 |
Cardiovascular Systems
CSII
|
- | 0.15 % | $ 844 M | USA |
 |
ShockWave Medical
SWAV
|
- | - | $ 12.3 B | USA |
 |
Inari Medical
NARI
|
- | - | $ 4.23 B | USA |
 |
Zynex
ZYXI
|
- | - | $ 21.1 M | USA |
 |
Abiomed
ABMD
|
- | - | $ 17.2 B | USA |
 |
Allied Healthcare Products
AHPI
|
- | 3.58 % | $ 2.21 M | USA |
 |
Titan Medical
TMDI
|
- | -26.32 % | $ 19.6 M | Canada |
 |
Natus Medical Incorporated
NTUS
|
- | 1.94 % | $ 1.05 B | USA |